噬血细胞性淋巴组织细胞增多症患者外周血中高迁移率族蛋白B1的表达及临床意义

陈影; 孙航; 娄世锋; 周慷; 张颖; 陈姝; 罗云; 沈燕; 龙贤梨; 邓建川

doi:10.16016/j.1000-5404.201906057

您当前的位置：

首页 >

文章列表页 >

噬血细胞性淋巴组织细胞增多症患者外周血中高迁移率族蛋白B1的表达及临床意义

专题报道：造血干细胞移植与细胞治疗 | 更新时间：2026-01-09

- 噬血细胞性淋巴组织细胞增多症患者外周血中高迁移率族蛋白B1的表达及临床意义
- Expression and clinical significance of high mobility group protein B1 in patients with hemophagocytic lymphohistiocytosis
- 第三军医大学学报 2019年41卷第23期页码：2307-2312
- 作者机构：
- 作者简介：
- 基金信息：
  
  国家自然科学基金面上项目(81871608)
- DOI：10.16016/j.1000-5404.201906057
  中图分类号：
- 收稿：2019-06-11，
  
  纸质出版：2019-12-25
- 稿件说明：
移动端阅览
陈影, 孙航, 娄世锋, 等. 噬血细胞性淋巴组织细胞增多症患者外周血中高迁移率族蛋白B1的表达及临床意义[J]. 第三军医大学学报, 2019,41(23):2307-2312.

Ying CHEN, Hang SUN, Shifeng LOU, et al. Expression and clinical significance of high mobility group protein B1 in patients with hemophagocytic lymphohistiocytosis[J]. Journal of Third Military Medical University, 2019, 41(23): 2307-2312.
陈影, 孙航, 娄世锋, 等. 噬血细胞性淋巴组织细胞增多症患者外周血中高迁移率族蛋白B1的表达及临床意义[J]. 第三军医大学学报, 2019,41(23):2307-2312. DOI： 10.16016/j.1000-5404.201906057.

Ying CHEN, Hang SUN, Shifeng LOU, et al. Expression and clinical significance of high mobility group protein B1 in patients with hemophagocytic lymphohistiocytosis[J]. Journal of Third Military Medical University, 2019, 41(23): 2307-2312. DOI： 10.16016/j.1000-5404.201906057.

摘要

Abstract

Objective

To detect the expression of high mobility group box 1 (HMGB1) in hemophagocytic lymphohistiocytosis (HLH) patients and explore its clinical significance in the disease.

Methods

A total of 26 HLH patients admitted in our hospital from July 2018 to May 2019 were recruited

and their clinical data were collected in this study. Thirty healthy volunteers were recruited as normal control. The serum level and mRNA level of HMGB1 in peripheral blood samples were measured by ELISA and quantitative real-time PCR

respectively. The correlation between HMGB1 level and clinical data were analyzed

and the optimal cut-off value

sensitivity and specificity of HMGB1 for the diagnosis of HLH were analyzed.

Results

The serum HMGB1 level was significantly higher in HLH patients than healthy volunteers (1 992.77±883.74

1 237.49±272.85 ng/mL

0.01)

]

. And the mRNA level of the molecule was also obviously increased in the HLH patients than the heal

thy control (4.56±2.10

2.34±1.32

0.05). The serum level of HMGB1 was negatively correlated with red blood cell count (

=-0.514 6

0.05)

hemoglobin level (

=-0.453 6

0.05) and platelet count (

=-0.505 5

0.05). The serum level of HMGB1 was notably higher in the HLH patients with hemophagocytosis in bone marrow than those without (2 246.27±935.14

1 422.38±317.33 ng/mL

0.05). The area under the curve (AUC) of HLH diagnosed by HMGB1 was 0.812 2 (

0.05) and the optimal cut-off value was 1 522 ng/mL

with a sensitivity of 69.23% and specificity of 86.67%.

Conclusion

HMGB1 is highly expressed in the peripheral blood of HLH patients

and can be used in the diagnosis

evaluation and prognosis of the disease.

关键词

Keywords

references

SHRIVASTAVA S MANSURE J J ALMAJED W The role of HMGB1 in radioresistance of bladder cancer Mol Cancer Ther 2016 15 3 471 479 10.1158/1535-7163.MCT-15-0581 SHRIVASTAVA S, MANSURE J J, ALMAJED W, et al . The role of HMGB1 in radioresistance of bladder cancer[J ] . Mol Cancer Ther, 2016, 15(3): 471-479. DOI:10.1158/1535-7163.MCT-15-0581.

QU L H CHEN C CHEN Y Y High-mobility group box 1 (HMGB1) and autophagy in acute lung injury (ALI): A review Med Sci Monit 2019 25 1828 1837 10.12659/MSM.912867 QU L H, CHEN C, CHEN Y Y, et al . High-mobility group box 1 (HMGB1) and auto phagy in acute lung injury (ALI): A review[J ] . Med Sci Monit, 2019, 25: 1828-1837. DOI:10.12659/MSM.912867.

TRIPATHI A SHRINET K KUMAR A HMGB1 protein as a novel target for cancer Toxicol Rep 2019 6 253 261 10.1016/j.toxrep.2019.03.002 TRIPATHI A, SHRINET K, KUMAR A. HMGB1 protein as a novel target for cancer[J]. Toxicol Rep, 2019, 6: 253-261. DOI:10.1016/j.toxrep.2019.03.002.

SHAH A R MUZZAFAR T ASSI R Hemophagocytic lymphohistiocytosis in adults: An under recognized entity BBA Clin 2017 7 36 40 10.1016/j.bbacli.2016.12.002 SHAH A R, MUZZAFAR T, ASSI R, et al . Hemophagocytic lymphohistiocytosis in adults: An under recognized entity[J ] . BBA Clin, 2017, 7: 36-40. DOI:10.1016/j.bbacli.2016.12.002.

SKINNER J YANKEY B SHELTON B K Hemophagocytic lymphohistiocytosis AACN Adv Crit Care 2019 30 2 151 164 10.4037/aacnacc2019463 SKINNER J, YANKEY B, SHELTON B K. Hemophagocytic lymphohistiocytosis[J]. AACN Adv Crit Care, 2019, 30(2): 151-164. DOI:10.4037/aacnacc2019463.

MUSUMECI D ROVIELLO G N MONTESARCHIO D An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies Pharmacol Ther 2014 141 3 347 357 10.1016/j.pharmthera.2013.11.001 MUSUMECI D, ROVIELLO G N, MONTESARCHIO D. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies[J]. Pharmacol Ther, 2014, 141(3): 347-357. DOI:10.1016/j.pharmthera.2013.11.001.

URBONAVICIUTE V FVRNROHR B G MEISTER S Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE J Exp Med 2008 205 13 3007 3018 10.1084/jem.20081165 URBONAVICIUTE V, FVRNROHR B G, MEISTER S, et al . Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE[J ] . J Exp Med, 2008, 205(13): 3007-3018. DOI:10.1084/jem.20081165.

DENG M H SCOTT M J FAN J Location is the key to function: HMGB1 in sepsis and trauma-induced inflammation J Leukoc Biol 2019 106 1 161 169 10.1002/JLB.3MIR1218-497R DENG M H, SCOTT M J, FAN J, et al . Location is the key to function: HMGB1 in sepsis and trauma-induced inflammation[J ] . J Leukoc Biol, 2019, 106(1): 161-169. DOI:10.1002/JLB.3MIR1218-497R.

TANAKA A ITO T KIBATA K Serum high-mobility group box 1 is correlated with interferon-α and may predict disease activity in patients with systemic lupus erythematosus Lupus 2019 28 9 1120 1127 10.1177/0961203319862865 TANAKA A, ITO T, KIBATA K, et al . Serum high-mobility group box 1 is correlated with interferon-α and may predict disease activity in patients with systemic lupus erythematosus[J ] . Lupus, 2019, 28(9): 1120-1127. DOI:10.1177/0961203319862865.

MARTINOTTI S PATRONE M RANZATO E Emerging roles for HMGB1 protein in immunity, inflammation, and cancer Immunotargets Ther 2015 4 101 109 10.2147/ITT.S58064 MARTINOTTI S, PATRONE M, RANZATO E. Emerging roles for HMGB1 protein in immunity, inflammation, and cancer[J]. Immunotargets Ther, 2015, 4: 101-109. DOI:10.2147/ITT.S58064.

XU B ZANG S C LI S Z HMGB1-mediated differential response on hippocampal neurotransmitter disorder and neuroinflammation in adolescent male and female mice following cold exposure Brain Behav Immun 2019 76 223 235 10.1016/j.bbi.2018.11.313 XU B, ZANG S C, LI S Z, et al . HMGB1-mediated differential response on hippocampal neurotransmitter disorder and neuroinflammation in adolescent male and female mice following cold exposure[J ] . Brain Behav Immun, 2019, 76: 223-235. DOI:10.1016/j.bbi.2018.11.313.

KIDA T SENO T NAGAHARA H Roles of high-mobility group box 1 and thrombin in murine pulmonary fibrosis and the therapeutic potential of thrombomodulin Am J Physiol Lung Cell Mol Physiol 2018 314 3 L473 L483 10.1152/ajplung.00287.2017 KIDA T, SENO T, NAGAHARA H, et al . Roles of high-mobility group box 1 and thrombin in murine pulmonary fibrosis and the therapeutic potential of thrombomodulin[J ] . Am J Physiol Lung Cell Mol Physiol, 2018, 314(3): L473-L483. DOI:10.1152/ajplung.00287.2017.

UGRINOVA I PASHEVA E HMGB1 protein: A therapeutic target inside and outside the cell Adv Protein Chem Struct Biol 2017 107 37 76 10.1016/bs.apcsb.2016.10.001 UGRINOVA I, PASHEVA E. HMGB1 protein: A therapeutic target inside and outside the cell[J]. Adv Protein Chem Struct Biol, 2017, 107: 37-76. DOI:10.1016/bs.apcsb.2016.10.001.

MANGANELLI V CAPOZZI A TRUGLIA S Elevated serum level of HMGB1 in patients with the antiphospholipid syndrome J Immunol Res 2017 2017 4570715 10.1155/2017/4570715 MANGANELLI V, CAPOZZI A, TRUGLIA S, et al . Elevated serum level of HMGB1 in patients with the antiphospholipid syndrome[J ] . J Immunol Res, 2017, 2017: 4570715. DOI:10.1155/2017/4570715.

YOON J H PARK S S JEON Y W Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy Haematologica 2019 104 2 269 276 10.3324/haematol.2018.198655 YOON J H, PARK S S, JEON Y W, et al . Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy[J ] . Haematologica, 2019, 104(2): 269-276. DOI:10.3324/haematol.2018.198655.

MINOIA F BOVIS F DAVÌ S Development and initial validation of the macrophage activation syndrome/primary hemophagocytic lymphohistiocytosis score, a diagnostic tool that differentiates primary hemophagocytic lymphohistiocytosis from macrophage activation syndrome J Pediatr 2017 189 72 78 10.1016/j.jpeds.2017.06.005 MINOIA F, BOVIS F, DAVÌ S, et al . Development and initial validation of the macrophage activation syndrome/primary hemophagocytic lymphohistiocytosis score, a diagnostic tool that differentiates primary hemophagocytic lymphohistiocytosis from macrophage activation syndrome[J ] . J Pediatr, 2017, 189: 72-78.e3. DOI:10.1016/j.jpeds.2017.06.005.

SU Y J WANG P N CHANG H Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases Eur J Haematol 2018 101 3 379 388 10.1111/ejh.13126 SU Y J, WANG P N, CHANG H, et al . Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases[J ] . Eur J Haematol, 2018, 101(3): 379-388. DOI:10.1111/ejh.13126.

HONG J Y KIM H J KO Y H Clinical features and treatment outcomes of intravascular large B-cell lymphoma: a single-center experience in Korea Acta Haematol 2014 131 1 18 27 10.1159/000351060 HONG J Y, KIM H J, KO Y H, et al . Clinical features and treatment outcomes of intravascular large B-cell lymphoma: a single-center experience in Korea[J ] . Acta Haematol, 2014, 131(1): 18-27. DOI:10.1159/000351060.

MADKAIKAR M SHABRISH S DESAI M Current updates on classification, diagnosis and treatment of hemophagocytic lymphohistiocytosis (HLH) Indian J Pediatr 2016 83 5 434 443 10.1007/s12098-016-2037-y MADKAIKAR M, SHABRISH S, DESAI M. Current updates on classification, diagnosis and treatment of hemophagocytic lymphohistiocytosis (HLH)[J]. Indian J Pediatr, 2016, 83(5):434-443. DOI: 10.1007/s12098-016-2037-y.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

抗水通道蛋白抗体1和5在原发性干燥综合征的诊断价值

沉默高迁移率族蛋白B1对胶质母细胞瘤细胞恶性生物学行为的抑制

基于微量量热法的无菌制剂快速无菌检查方法研究

噬菌体Chy2生物扩增法的建立及其检测效果的评价

漏声表面波传感器生物信号放大系统的研究